Cugene

Cugene is a private, clinical-stage biotech founded in 2018, focusing on precision-engineered immunotherapies for autoimmune diseases and cancer. Its core technology platform involves immuno-engineering to create selective biologics, including engineered cytokines and bispecific antibodies with proprietary masking domains. The lead program, CUG252, is a Treg-selective IL-2 for autoimmune conditions, while its oncology pipeline features TILKine™ and VitoKine™ bispecific platforms designed to transform cold tumors. The company is science-driven, led by an experienced team, and is currently in the pre-clinical to early clinical development stage.

Precision protein engineering platform for creating selective biologics, including engineered cytokines (e.g., Treg-selective IL-2) and bispecific/multi-functional antibodies (TILKine™, VitoKine™) integrated with proprietary masking technology for tumor-localized activation.

Cugene operates in highly competitive spaces. In autoimmune IL-2 therapy, it competes with companies like Nektar Therapeutics, Anokion, and large pharma. In oncology bispecifics and TIL-targeting therapies, it faces competition from numerous biotechs (e.g., Immunocore, IGM Biosciences) and major pharmaceutical companies with extensive immuno-oncology pipelines.